Trial · NCT03675737
Adverse events1,203
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,203
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 325 | 785 | 512 |
| other | Anaemia | Blood and lymphatic system disorders | Placebo + Chemotherapy (FP or CAPOX Regimen) | 282 | 787 | 413 |
| other | Anaemia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 3 | 12 | 4 |
| other | Leukopenia | Blood and lymphatic system disorders | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 47 | 785 | 76 |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo + Chemotherapy (FP or CAPOX Regimen) | 42 | 787 | 79 |
| other | Leukopenia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 2 | 12 | 3 |
| other | Lymphopenia | Blood and lymphatic system disorders | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 28 | 785 | 38 |
| other | Lymphopenia | Blood and lymphatic system disorders | Placebo + Chemotherapy (FP or CAPOX Regimen) | 16 | 787 | 25 |
| other | Lymphopenia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 3 | 12 | 3 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 146 | 785 | 309 |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo + Chemotherapy (FP or CAPOX Regimen) | 141 | 787 | 294 |
| other | Neutropenia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 2 | 12 | 4 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 95 | 785 | 147 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo + Chemotherapy (FP or CAPOX Regimen) | 83 | 787 | 137 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pembrolizumab Second Course | 2 | 12 | 2 |
| other | Tinnitus | Ear and labyrinth disorders | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 20 | 785 | 23 |
| other | Tinnitus | Ear and labyrinth disorders | Placebo + Chemotherapy (FP or CAPOX Regimen) | 15 | 787 | 16 |
| other | Tinnitus | Ear and labyrinth disorders | Pembrolizumab Second Course | 1 | 12 | 1 |
| other | Hyperthyroidism | Endocrine disorders | Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) | 43 | 785 | 44 |
| other | Hyperthyroidism | Endocrine disorders | Placebo + Chemotherapy (FP or CAPOX Regimen) | 13 | 787 | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03675737/events